Mesothelioma Tests and Biopsy: How the Diagnosis Is Confirmed
Diagnosing mesothelioma usually requires several steps. Imaging can reveal abnormal tissue, pleural thickening or fluid buildup, but imaging alone cannot confirm the disease. Doctors often need fluid or tissue samples that can be examined by an experienced pathologist.
The exact testing pathway depends on where the suspected tumor is located, the patient’s health, imaging findings and whether enough material can be obtained for pathology and additional laboratory testing.
● Medical review pending — last updated July 27, 2026Key takeaway
Most patients need an adequate tissue sample to confirm mesothelioma and determine its histologic subtype. In selected cases, an expert diagnosis may be possible from a high-quality fluid cell block supported by immunohistochemical and molecular tests. Tissue may still be needed to demonstrate invasion or guide treatment decisions.
How Mesothelioma Is Diagnosed
The diagnostic process may include a review of symptoms and medical history, an occupational and asbestos exposure history, a physical examination, imaging, fluid sampling when an effusion is present, tissue biopsy, pathology and immunohistochemistry, selected molecular or genetic tests, and staging with multidisciplinary review.
No single symptom, scan, routine blood test or exposure history can confirm mesothelioma. Some diagnostic and staging tests may overlap or occur in a different order depending on the patient’s condition, the tumor location and the medical team’s findings.
Symptoms & History
Doctors review symptoms, duration, and any occupational or household asbestos exposure history.
Imaging
Chest X-ray, CT, PET-CT, MRI or ultrasound may be used to look for abnormalities worth investigating further.
Fluid or Tissue Sampling
Fluid analysis or a tissue biopsy is generally needed to obtain material for pathology review.
Pathology Confirmation
A pathologist examines the sample, applies immunohistochemistry, and determines the histologic subtype.
Staging & Multidisciplinary Review
The medical team evaluates the extent of disease and discusses the case together before treatment planning.
Initial Medical Evaluation
Before ordering imaging or biopsy, a physician typically asks about current symptoms and how long they have lasted, previous occupations such as construction, shipyard, industrial or insulation work, military service, and possible household asbestos exposure. The physician may also ask about prior chest or abdominal disease, previous cancers, current medications including blood-thinning medicines, smoking history, and overall health and functional status.
A history of asbestos exposure increases clinical suspicion but does not prove that a person has mesothelioma. Many people with a history of exposure never develop the disease, and some patients diagnosed with mesothelioma have no clearly identified exposure. This initial conversation helps the medical team decide which diagnostic steps make sense next, based on reported symptoms and the person’s exposure and asbestos exposure history. Readers who want a broader introduction can also review our mesothelioma overview.
Imaging Tests Used During Diagnosis
Imaging may strongly suggest mesothelioma, but it cannot confirm the disease by itself. Different scans provide different information and are often used together.
Chest X-ray
May reveal pleural fluid, pleural thickening, reduced lung expansion or another chest abnormality. An X-ray cannot confirm mesothelioma.
CT Scan
Commonly used to examine the pleura, lungs, chest wall, diaphragm, mediastinum, lymph nodes and, when relevant, abdominal structures. CT may also guide a needle biopsy. CT findings are not specific to mesothelioma.
PET-CT Scan
May help identify metabolically active areas, evaluate possible lymph node involvement, look for distant spread, and select a biopsy target in selected cases. Infection and inflammation can also appear active on PET imaging, so it is not used as a stand-alone diagnostic test.
MRI
May provide additional detail when doctors need to assess possible involvement of the diaphragm, chest wall, spine, blood vessels or nearby soft tissues. MRI is not required for every patient.
Ultrasound
Can detect pleural or abdominal fluid, help guide thoracentesis or paracentesis, guide selected needle biopsies, and reduce the risk of sampling the wrong location.
Imaging has limits
Imaging may strongly suggest mesothelioma, but benign asbestos-related disease, infection, inflammation and other cancers can produce similar appearances. Pathology is generally required for confirmation.
Fluid Tests and Cytology
When fluid builds up around the lungs, abdomen or heart, doctors may remove it through thoracentesis (fluid from around the lung), paracentesis (fluid from the abdomen) or, in selected cases, pericardiocentesis (fluid from around the heart). Removing fluid may improve breathing, reduce pressure, relieve discomfort, and provide cells for laboratory examination.
A cell block concentrates cells from the fluid into a preparation that can be processed more like a small tissue sample. This may allow immunohistochemical and selected molecular tests.
Important: A negative fluid cytology result does not rule out mesothelioma. The sample may not contain enough abnormal cells, and malignant mesothelial cells may be difficult to distinguish from reactive cells.
Even when abnormal mesothelial cells are identified, additional tissue sampling may be needed to demonstrate invasion, determine the histologic subtype, exclude another cancer or obtain enough material for treatment planning. In selected cases, an expert diagnosis may be possible from an adequate fluid cell block supported by morphology, immunohistochemistry and molecular testing. However, tissue biopsy remains necessary for many patients.
Types of Mesothelioma Biopsy
Several biopsy methods can obtain tissue for pathology review. The most appropriate biopsy method depends on the location of the suspected tumor, the patient’s health, the amount of fluid present, previous test results, procedural risk and the amount of tissue needed for complete pathology testing.
| Procedure | How the Sample Is Obtained | Common Use | Main Advantage | Main Limitation |
|---|---|---|---|---|
| Image-guided core needle biopsy | A radiologist uses CT or ultrasound guidance to pass a hollow needle into an abnormal area and obtain small cores of tissue. | Accessible pleural, chest wall or abdominal abnormality | Less invasive, often local anesthesia, shorter recovery | Sample may be small; may not demonstrate invasion; additional biopsy sometimes needed |
| Medical thoracoscopy | A trained specialist inserts a small camera into the chest through a small incision, usually with local anesthesia and conscious sedation. | Suspected pleural mesothelioma | Direct pleural inspection; multiple, larger samples; can drain fluid | More involved than a needle biopsy; not appropriate for every patient |
| Video-assisted thoracoscopic surgery (VATS) | A surgical procedure generally performed under general anesthesia using a small camera and instruments inserted through the chest wall. | When surgical assessment or larger samples are needed | Direct pleural inspection with multiple tissue samples | Requires general anesthesia and surgical recovery |
| Laparoscopy | Small abdominal incisions allow direct inspection of the peritoneum and collection of multiple tissue samples. | Suspected peritoneal mesothelioma | Direct visualization of abdominal abnormalities | Surgical procedure with associated recovery time |
| Surgical (open) biopsy | An open surgical approach obtains a larger tissue specimen. | When less invasive sampling was inadequate or the area is difficult to reach | Larger specimen for pathology | More invasive; not a routine first-line procedure |
| Lymph node sampling | EBUS-guided biopsy, EUS-guided biopsy, mediastinoscopy, image-guided needle biopsy or surgical sampling in selected cases. | Staging and treatment planning | Helps exclude another type of cancer | Method depends on node location and accessibility |
Medical thoracoscopy is usually performed with local anesthesia and conscious sedation, while video-assisted thoracoscopic surgery, or VATS, is generally performed under general anesthesia. Both procedures allow doctors to inspect the pleura directly and obtain multiple tissue samples. Neither method is universally superior; the choice depends on the clinical situation.
What Happens During a Biopsy?
Preparing for the Procedure
The team typically reviews medical history, medications including blood thinners, allergies, blood tests and imaging, and discusses fasting instructions, the sedation or anesthesia plan, transportation home and informed consent.
The Procedure Itself
Depending on the biopsy method, the procedure may use local anesthesia, conscious sedation or general anesthesia. The medical team selects the approach based on the type of biopsy being performed.
Recovery and Monitoring
Monitoring may include blood pressure, heart rate, oxygen level, breathing, pain, bleeding, sedation recovery, and chest imaging after selected chest procedures.
Safety note: Patients should not stop prescribed medications unless their medical team specifically instructs them to do so.
Potential risks depend on the procedure and may include bleeding, infection, pain, an air leak or pneumothorax after a chest biopsy, and complications related to sedation or anesthesia. The medical team should explain the individual benefits and risks before the procedure.
Contact the medical team promptly for worsening shortness of breath, severe or increasing pain, fever, significant bleeding or any symptom specifically listed in the discharge instructions.
How Pathologists Confirm Mesothelioma
A pathologist evaluates tissue architecture, cell appearance, growth pattern, evidence of tissue invasion, tumor location, histologic subtype, immunohistochemical staining, molecular or genetic findings when needed, and clinical and imaging information. A confident diagnosis integrates morphology, immunohistochemistry, clinical findings, imaging and ancillary molecular tests when appropriate.
Histologic Patterns
Pathologists describe mesothelioma using three principal histologic patterns. Classification depends on the tissue represented in the biopsy and may be more difficult in very small samples.
Epithelioid
Usually composed of cells that resemble epithelial cells. It is the most common histologic pattern. Individual outcomes vary and are not predicted by subtype alone.
Sarcomatoid
Usually composed of spindle-shaped tumor cells. It may resemble sarcoma, reactive fibrosis or other spindle-cell tumors, which can make diagnosis more challenging.
Biphasic
Contains both epithelioid and sarcomatoid components. Classification depends on how much of each pattern is represented in the tissue sampled.
Immunohistochemistry
Immunohistochemistry uses antibodies that attach to specific proteins in the tissue. The staining pattern helps determine whether the tumor has mesothelial features and helps distinguish mesothelioma from lung cancer, metastatic cancer and other conditions.
Common mesothelial markers include calretinin, WT1, D2-40 and cytokeratin 5/6. Markers that may help identify or exclude epithelial carcinomas include claudin-4, CEA, TTF-1, MOC-31 and BerEP4. Not all markers are used in every case — the exact antibody panel varies according to the tumor location, tissue appearance, patient characteristics and cancers being considered. No marker should be interpreted in isolation.
Immunohistochemistry can help establish mesothelial lineage and exclude other tumors, but mesothelial markers alone do not prove that a proliferation is malignant. Evidence of tissue invasion and selected ancillary tests may be needed to distinguish malignant mesothelioma from a reactive mesothelial process. Pathologists commonly use a panel of multiple mesothelial and epithelial markers rather than a single stain.
Advanced pathology tests
BAP1 immunohistochemistry: Loss of BAP1 staining may support malignancy in the appropriate context. Retained BAP1 does not exclude mesothelioma.
MTAP immunohistochemistry: Loss of MTAP staining may support malignancy and may correlate with CDKN2A deletion in selected settings. MTAP testing is not perfectly sensitive or specific.
CDKN2A (p16) FISH testing: Homozygous deletion of CDKN2A may support a malignant mesothelial diagnosis.
Loss of BAP1 or MTAP expression and homozygous deletion of CDKN2A can support a diagnosis of malignant mesothelioma in the appropriate morphologic and clinical context. Retained BAP1 or MTAP expression, or the absence of CDKN2A deletion, does not rule out mesothelioma. These tests are most useful after the cells have been shown to be mesothelial, and must be interpreted together with tissue appearance, immunohistochemistry, imaging and clinical findings. Molecular testing does not replace expert pathology review.
Can Blood Tests Diagnose Mesothelioma?
Researchers have studied biomarkers such as soluble mesothelin-related peptides, fibulin-3, osteopontin and other circulating tumor markers. Blood biomarkers may provide supplementary information in selected clinical or research settings, but they are not sufficiently reliable to confirm or exclude mesothelioma by themselves. They do not replace imaging, biopsy or pathology review, and they are not established stand-alone screening tests for the general population. Experimental liquid biopsy technology is not yet established standard care, and we do not recommend commercial blood tests as a substitute for evaluation by a medical team.
Understanding the Biopsy Report
A pathology report commonly includes the biopsy site, specimen type, whether malignant cells were identified, whether mesothelial differentiation was identified, evidence of invasion, histologic pattern, immunohistochemistry results, molecular findings, sample adequacy, differential diagnosis, recommended additional testing and expert consultation comments.
Ask for clarification if the report says:
- Suspicious for mesothelioma
- Atypical mesothelial proliferation
- Mesothelial proliferation of uncertain significance
- Cannot exclude malignancy
- Insufficient tissue
- Limited sample
- Additional sampling recommended
- Expert consultation recommended
- Correlation with imaging recommended
These phrases do not necessarily represent a final confirmed diagnosis, and a second procedure may occasionally be required if the sample is inadequate. Once a diagnosis is confirmed, the medical team typically moves on to staging, discusses treatment options, and may address questions about prognosis. Patients can also find a mesothelioma specialist to guide these next steps.
When to Request a Second Pathology Review
Mesothelioma is uncommon and can resemble benign reactive mesothelial proliferation, lung adenocarcinoma, metastatic carcinoma, sarcoma and other pleural or peritoneal tumors. Discussing expert review may be worthwhile when the biopsy is inconclusive, the sample is small, the wording is uncertain, immunohistochemistry is conflicting, clinical and imaging findings do not match the pathology report, surgery or another major treatment is being considered, the patient wants confirmation before starting treatment, or additional molecular testing may be needed.
An expert pathology review does not mean that the original pathologist made an error. Mesothelioma can be diagnostically challenging, and consultation may help confirm the findings or identify additional tests.
Need help finding an experienced mesothelioma team?
Questions to Ask the Medical Team
- Which test should I have next?
- Why are you recommending this biopsy method?
- Could a less invasive biopsy provide enough tissue?
- Will the sample be large enough for complete pathology testing?
- Will the sample be tested for histologic subtype?
- Will immunohistochemistry be performed?
- Could molecular tests be needed?
- What type of anesthesia or sedation will be used?
- What are the most relevant risks in my situation?
- How should I prepare?
- When should I stop eating or drinking?
- Should I change any medications?
- When should I expect the results?
- Will an experienced thoracic or mesothelioma pathologist review the sample?
- Could I need another biopsy if the result is inconclusive?
- Which symptoms should I report after the procedure?
- Will tissue be preserved for additional testing?
- Can the slides or tissue block be sent for a second opinion?
What Happens After Diagnosis?
After pathology confirmation, the medical team may perform additional testing to evaluate tumor extent, chest wall or diaphragm involvement, lymph node involvement, distant spread, surgical eligibility, lung and heart function, general health, and ability to tolerate treatment. The case is often discussed by a multidisciplinary team involving thoracic specialists, oncologists, surgeons, radiologists, pathologists, pulmonologists, radiation oncologists and supportive care professionals.
Related reading: stages, treatment, prognosis, Find a Specialist and Patient Resources.
A Confirmed Diagnosis Is the Beginning of the Treatment Plan
Once the pathology results are available, a mesothelioma specialist can explain the cancer type, histologic pattern, extent of disease and available treatment options. Patients and families may also benefit from practical, financial and legal support related to asbestos exposure.
Frequently Asked Questions
Is a biopsy always required to diagnose mesothelioma?
Most patients need a tissue biopsy to confirm mesothelioma and determine its histologic subtype. In selected cases, an expert diagnosis may be possible from an adequate fluid cell block supported by immunohistochemical and molecular tests. However, tissue is often still needed to demonstrate invasion and guide treatment decisions.
Can a CT scan confirm mesothelioma?
No. A CT scan can identify suspicious abnormalities, assess their location and guide further testing, but pathology is normally needed to confirm mesothelioma.
Can pleural fluid show mesothelioma?
Sometimes. Abnormal mesothelial cells may be identified in pleural fluid, particularly when an adequate cell block is available. However, fluid cytology may be negative or inconclusive, and a tissue biopsy may still be needed.
Which biopsy is best for pleural mesothelioma?
There is no single best biopsy procedure for every patient. Medical thoracoscopy or VATS can provide larger samples, while an image-guided core biopsy may be appropriate when an abnormality is safely accessible. The decision depends on imaging, health status, procedural risk and the amount of tissue needed.
What is the difference between medical thoracoscopy and VATS?
Medical thoracoscopy is usually performed with local anesthesia and conscious sedation. VATS is a surgical procedure generally performed under general anesthesia. Both allow direct inspection of the pleura and collection of tissue samples.
How long do biopsy results take?
Timing varies by hospital, specimen type and the number of special stains or consultations required. Preliminary results may be available within several business days, while complex pathology reviews may take longer.
Can a mesothelioma biopsy be inconclusive?
Yes. Small samples, limited tissue architecture, tumor location and overlap with benign or other malignant conditions can make interpretation difficult. Additional testing or another biopsy may be recommended.
Should the biopsy be reviewed by a specialist?
Because mesothelioma is uncommon and diagnostically challenging, review by a pathologist experienced in pleural or mesothelial tumors may be valuable, particularly before major treatment decisions.
Can a blood test replace a biopsy?
No established routine blood test can currently replace tissue or cytologic diagnosis supported by specialist pathology.
Does a normal BAP1 result rule out mesothelioma?
No. Retained BAP1 staining does not rule out mesothelioma. BAP1, MTAP and CDKN2A findings must be interpreted with morphology, other immunohistochemical stains, imaging and clinical information.
Medical disclaimer: This page provides general educational information and is not a substitute for diagnosis, testing or treatment from a qualified medical professional. Decisions about imaging, biopsy and pathology testing should be made by the patient and their medical team based on individual circumstances.
Sources and Medical Review
Written by the MesotheliomaFeed Editorial Team, using publicly available medical and pathology literature. Medical review status: Medical review pending. Last updated: July 27, 2026.
- National Cancer Institute — Mesothelioma Treatment (PDQ)
- American Cancer Society — Tests for Malignant Mesothelioma
- International Mesothelioma Interest Group — guidelines on pathologic diagnosis of mesothelioma
- College of American Pathologists — protocol for examination of specimens from mesothelioma
- International Collaboration on Cancer Reporting — mesothelioma reporting dataset
- American Society of Clinical Oncology — clinical guidance on mesothelioma diagnosis and management
- European Respiratory Society — statement on the management of malignant pleural mesothelioma
- Peer-reviewed pathology literature on BAP1, MTAP and CDKN2A testing in mesothelioma